The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model
BRCA testing and subsequent treatment with olaparib results in fewer recurrences in eBC and a longer life expectancy vs no testing and no treatment, suggesting there is substantial clinical value in widespread BRCA testing for this population.
Authors
- René Veenstra (ORCID: https://orcid.org/0000-0001-6686-6307)
- Adam Kasle
- Xiaoqing Xu (ORCID: https://orcid.org/0000-0001-8294-6307)
- Qixin Li (ORCID: https://orcid.org/0009-0006-9752-4696)
- Amy Tung
Institutions
- University of Washington (US)
- Hetao College (CN)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1080/13696998.2025.2583870
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00